Project Grant K22CA303684
Award Date 7/16/26
Completion Date 6/30/29
Dollars Obligated $192K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
- Federal Grant Award Summary Seattle Children's Research Institute received a $470,759 Project Grant from the National Cancer Institute (Cancer Treatment Research program, CFDA 93.395) effective September 1, 2025 through August 31, 2027. The award supports development of an innovative CAR-T (Chimeric Antigen Receptor T-cell) immunotherapy platform designed to overcome T-cell exhaustion in solid tumor treatment, specifically targeting hepatocellular carcinoma patients. The research deliverables...
- Federal Project Grant Award Summary Seattle Children's Research Institute received a $772,757 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded on July 15, 2026, with an ultimate completion date of June 30, 2031. The award funds research development and evaluation of T Cell Engagers (TCEs)—a class of protein therapeutics designed to treat pediatric and adult brain tumors, including diffuse midline gliomas, recurrent...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Fred Hutchinson Cancer Center a $723,547 Project Grant under the Cancer Biology Research program (CFDA 93.396) on June 9, 2026, for a five-year research initiative extending through May 31, 2031. The grant funds fundamental research to delineate the role of 5' untranslated regions (5' UTRs) in prostate cancer clonality—specifically, how these regulatory RNA elements modulate protein synthesis and influence clonal...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Fred Hutchinson Cancer Center $169,776 under the Cancer Research Manpower program (CFDA 93.398) for a two-year project (August 1, 2025–July 31, 2027) titled "Unraveling Myeloid-Mediated Mechanisms of Immunotherapy Resistance in Prostate Cancer Bone Metastases at Single-Cell Resolution." This project grant funds biomedical research training and investigator-initiated research focused on identifying and...
- Federal Grant Award Summary Fred Hutchinson Cancer Center received a $487,902 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded July 10, 2026, with an ultimate completion date of June 30, 2031. The award supports comprehensive research to decipher cancer pleiotropy—the shared genetic mechanisms underlying multiple cancer types—by leveraging large-scale genomic datasets and biobanks. The project will conduct...
- Federal Project Grant Award Summary Cellchorus Inc. received a $399,625 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through August 31, 2027. The awardee will develop functional signatures of post-infusion Chimeric Antigen Receptor (CAR) T cells to enable early prediction of patient response in relapsed/refractory large B cell lymphoma (R/RLBCL). The project leverages Cellchorus's proprietary Time-lapse...
- Federal Grant Award Summary The National Cancer Institute awarded a $399,829 Project Grant to The Washington University (Office of Sponsored Research Services) under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026, through March 31, 2028. This project focuses on the rational design of next-generation engineered T cells to enhance cancer immunotherapy by addressing a critical limitation in current chimeric antigen receptor (CAR) T cell treatments—limited...
- Federal Project Grant Award Summary Funding Agency & Program: The National Cancer Institute (NCI) awarded $399,829 under the Cancer Treatment Research program (CFDA 93.395) on May 13, 2026, to Washington University's Office of Sponsored Research Services. Research Deliverables: This project grant funds mechanistic research and development of a novel dendritic cell (DC)-based cancer immunotherapy designated AB7H3-TLR4 CAR-DCs (Chimeric Antigen Receptor Dendritic Cells). The research...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $692,368 Project Grant to Fred Hutchinson Cancer Center under the Cancer Cause and Prevention Research program (CFDA 93.393) on June 1, 2026, with a completion date of May 31, 2031. The project, titled "The MYC Transcription Factor Network: Elucidating Oncogenic and Tumor Suppressive Pathways," funds basic biomedical research designed to elucidate how dysregulation of the MYC transcription factor...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $172,889 to The Regents of the University of California, San Francisco (UCSF) under the Cancer Research Manpower program (CFDA 93.398) on January 12, 2026, with a completion date of March 31, 2027. This Project Grant supports research training and workforce development focused on developing optimized chimeric antigen receptor (CAR) T-cell therapies for acute myeloid leukemia (AML). The funded research employs...